Open AccessSingle-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study
Author(s) -
KlausPeter Dieckmann,
Tomáš Pokrivčák,
Lajos Gergely,
David E. Niehaus,
Inken Dralle-Filiz,
Cord Matthies,
Tamás Dienes,
Stefanie Zschäbitz,
Pia Paffenholz,
Tanja Gschliesser,
Renate Pichler,
Michal Mego,
Pia Bader,
Friedemann Zengerling,
Julia Heinzelbecker,
Philipp Krausewitz,
Susanne Krege,
Gaetano Aurilio,
Cem Aksoy,
Marcus Hentrich,
Christoph Seidel,
Péter Törzsök,
Tim Nestler,
Matthäus Majewski,
Andreas Hiester,
Tomáš Büchler,
Sonia Vallet,
Hana Študentová,
Sandra Schönburg,
Dora Niedersüß-Beke,
Julia Ring,
Emanuela Trenti,
Axel Heidenreich,
Christian Wülfing,
Hendrik Isbarn,
Uwe Pichlmeier,
Martin Pichler
Publication year - 2022
Publication title -
therapeutic advances in medical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 49
eISSN - 1758-8359
pISSN - 1758-8340
DOI - 10.1177/17588359221086813
Subject(s) - medicine , etoposide , population , bleomycin , testicular cancer , regimen , oncology , proportional hazards model , germ cell tumors , hazard ratio , confidence interval , surgery , chemotherapy , environmental health
Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to pT2 was significantly associated with relapse rate.Conclusion: The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.